146 research studies affirm naturally acquired immunity to covid-19

We should not force covid vaccines on anyone when the evidence shows that naturally acquired immunity is equal to or more robust and superior to existing vaccines. Instead, we should respect the right of the bodily integrity of persons to decide for themselves.

Public health officials and the medical establishment with the help of the politicized media are misleading the public with assertions that the covid-19 shots provide greater protection than natural immunity. CDC Director Rochelle Walensky, for example, was deceptive in her October 2020 published Lancet statement that “there is no evidence for lasting protective immunity to SARS-CoV-2 following natural infection” and that “the consequence of waning immunity would present a risk to vulnerable populations for the indefinite future.”

Immunology and virology have taught us over a century that natural immunity confers protection against a respiratory virus’s outer coat proteins, and not just one, e.g. the SARS-CoV-2 spike glycoprotein. There is even strong evidence for the persistence of antibodies. Even the CDC recognizes natural immunity for chicken-pox and measles, mumps, and rubella, but not for covid-19.

The vaccinated are showing viral loads (very high) similar to the unvaccinated (Acharya et al. and Riemersma et al.), and the vaccinated are as infectious. Riemersma et al. also report Wisconsin data that corroborate how the vaccinated persons who get infected with the Delta variant can potentially (and are) transmit(ting) SARS-CoV-2 to others (potentially to the vaccinated and unvaccinated).

This troubling situation of the vaccinated being infectious and transmitting the virus emerged in seminal nosocomial outbreak papers by Chau et al. (HCWs in Vietnam), the Finland hospital outbreak (spread among HCWs and patients), and the Israel hospital outbreak (spread among HCWs and patients).

These studies also revealed that the PPE and masks were essentially ineffective in the healthcare setting. Again, the Marek’s disease in chickens and the vaccination situation explains what we are potentially facing with these leaky vaccines (increased transmission, faster transmission, and more ‘hotter’ variants).

Moreover, existing immunity should be assessed before any vaccination, via an accurate, dependable, and reliable antibody test (or T cell immunity test) or be based on documentation of prior infection (a previous positive PCR or antigen test). Such would be evidence of immunity that is equal to that of vaccination and the immunity should be provided the same societal status as any vaccine-induced immunity.

This will function to mitigate the societal anxiety with the forced vaccine mandates and societal upheaval due to job loss, denial of societal privileges etc. Tearing apart the vaccinated and the unvaccinated in a society, separating them, is not medically or scientifically supportable.

The Brownstone Institute previously documented 30 studies on natural immunity as it relates to covid-19. This follow-up chart is the most updated and comprehensive library list of 146 of the highest-quality, complete, most robust scientific studies and evidence reports/position statements on natural immunity as compared to the covid-19 vaccine-induced immunity and allow you to draw your own conclusion.

This represents the judged trustworthy ‘body of evidence’ that includes peer-reviewed studies and high-quality literature and reporting that contributes to that body of evidence. The aim here is to share and inform for your own decision-making.

Evidence on natural immunity versus covid-19 vaccine induced immunity:

1) “Necessity Of Covid-19 Vaccination In Previously Infected Individuals”, Shrestha, 2021:

“Cumulative incidence of covid-19 was examined among 52,238 employees in an American healthcare system. The cumulative incidence of SARS-CoV-2 infection remained almost zero among previously infected unvaccinated subjects, previously infected subjects who were vaccinated, and previously uninfected subjects who were vaccinated, compared with a steady increase in cumulative incidence among previously uninfected subjects who remained unvaccinated. Not one of the 1359 previously infected subjects who remained unvaccinated had a SARS-CoV-2 infection over the duration of the study. persons who have had SARS-CoV-2 infection are unlikely to benefit from covid-19 vaccination…”

2) “SARS-CoV-2-Specific T Cell Immunity In Cases Of Covid-19 And SARS, And Uninfected Controls”, Le Bert, 2020:

“Studied T cell responses against the structural (nucleocapsid (N) protein) and non-structural (NSP7 and NSP13 of ORF1) regions of SARS-CoV-2 in persons convalescing from coronavirus disease 2019 (covid-19) (n = 36). In all of these individuals, we found CD4 and CD8 T cells that recognized multiple regions of the N protein… showed that patients (n = 23) who recovered from SARS possess long-lasting memory T cells that are reactive to the N protein of SARS-CoV 17 years after the outbreak of SARS in 2003; these T cells displayed robust cross-reactivity to the N protein of SARS-CoV-2.”

3) “Comparing SARS-CoV-2 Natural Immunity To Vaccine-Induced Immunity: Reinfections Versus Breakthrough Infections”, Gazit, 2021:

“A retrospective observational study comparing three groups: (1) SARS-CoV-2-naïve persons who received a two-dose regimen of the BioNTech/Pfizer mRNA BNT162b2 vaccine, (2) previously infected persons who have not been vaccinated, and (3) previously infected and single dose vaccinated persons found para a 13 fold increased risk of breakthrough Delta infections in double vaccinated persons, and a 27 fold increased risk for symptomatic breakthrough infection in the double vaccinated relative to the natural immunity recovered persons…the risk of hospitalization was 8 times higher in the double vaccinated (para)…this analysis demonstrated that natural immunity affords longer lasting and stronger protection against infection, symptomatic disease and hospitalization due to the Delta variant of SARS-CoV-2, compared to the BNT162b2 two-dose vaccine-induced immunity.”

4) “Highly Functional Virus-Specific Cellular Immune Response In Asymptomatic SARS-CoV-2 Infection”, Le Bert, 2021:

“Studied SARS-CoV-2–specific T cells in a cohort of asymptomatic (n = 85) and symptomatic (n = 75) covid-19 patients after seroconversion… thus, asymptomatic SARS-CoV-2–infected persons are not characterized by weak antiviral immunity; on the contrary, they mount a highly functional virus-specific cellular immune response.”

5) “Large-Scale Study Of Antibody Titer Decay Following BNT162b2 MRNA Vaccine Or SARS-CoV-2 Infection”, Israel, 2021:

“A total of 2,653 persons fully vaccinated by two doses of vaccine during the study period and 4,361 convalescent patients were included. Higher SARS-CoV-2 IgG antibody titers were observed in vaccinated persons (median 1581 AU/mL IQR [533.8-5644.6]) after the second vaccination, than in convalescent persons (median 355.3 AU/mL IQR [141.2-998.7]; p<0.001). In vaccinated subjects, antibody titers decreased by up to 40% each subsequent month while in convalescents they decreased by less than 5% per month…this study demonstrates persons who received the Pfizer-BioNTech mRNA vaccine have different kinetics of antibody levels compared to patients who had been infected with the SARS-CoV-2 virus, with higher initial levels but a much faster exponential decrease in the first group”.

6) “SARS-CoV-2 Re-Infection Risk In Austria”, Pilz, 2021:

Researchers recorded “40 tentative re-infections in 14, 840 covid-19 survivors of the first wave (0.27%) and 253 581 infections in 8, 885, 640 persons of the remaining general population (2.85%) translating into an odds ratio (95% confidence interval) of 0.09 (0.07 to 0.13)…relatively low re-infection rate of SARS-CoV-2 in Austria. Protection against SARS-CoV-2 after natural infection is comparable with the highest available estimates on vaccine efficacies.” Additionally, hospitalization in only five out of 14,840 (0.03%) people and death in one out of 14,840 (0.01%) (tentative re-infection).

7) “MRNA Vaccine-Induced SARS-CoV-2-Specific T Cells Recognize B.1.1.7 And B.1.351 Variants But Differ In Longevity And Homing Properties Depending On Prior Infection Status”, Neidleman, 2021:

“Spike-specific T cells from convalescent vaccinees differed strikingly from those of infection-naïve vaccinees, with phenotypic features suggesting superior long-term persistence and ability to home to the respiratory tract including the nasopharynx. These results provide reassurance that vaccine-elicited T cells respond robustly to the B.1.1.7 and B.1.351 variants, confirm that convalescents may not need a second vaccine dose.”

8) “Good News: Mild Covid-19 Induces Lasting Antibody Protection”, Bhandari, 2021:

“Months after recovering from mild cases of covid-19, people still have immune cells in their body pumping out antibodies against the virus that causes covid-19, according to a study from researchers at Washington University School of Medicine in St. Louis. Such cells could persist for a lifetime, churning out antibodies all the while. The findings, published May 24 in the journal Nature, suggest that mild cases of covid-19 leave those infected with lasting antibody protection and that repeated bouts of illness are likely to be uncommon.”

9) “Robust Neutralizing Antibodies To SARS-CoV-2 Infection Persist For Months”, Wajnberg, 2021:

“Neutralizing antibody titers against the SARS-CoV-2 spike protein persisted for at least 5 months after infection. Although continued monitoring of this cohort will be needed to confirm the longevity and potency of this response, these preliminary results suggest that the chance of reinfection may be lower than is currently feared.”

10) “Evolution Of Antibody Immunity To SARS-CoV-2”, Gaebler, 2020:

“Concurrently, neutralizing activity in plasma decreases by five-fold in pseudo-type virus assays. In contrast, the number of RBD-specific memory B cells is unchanged. Memory B cells display clonal turnover after 6.2 months, and the antibodies they express have greater somatic hypermutation, increased potency and resistance to RBD mutations, indicative of continued evolution of the humoral response…we conclude that the memory B cell response to SARS-CoV-2 evolves between 1.3 and 6.2 months after infection in a manner that is consistent with antigen persistence.”

11) “Persistence Of Neutralizing Antibodies A Year After SARS-CoV-2 Infection In Humans”, Haveri, 2021:

“Assessed the persistence of serum antibodies following WT SARS-CoV-2 infection at 8 and 13 months after diagnosis in 367 individuals… found that NAb against the WT virus persisted in 89% and S-IgG in 97% of subjects for at least 13 months after infection.”

 

yogaesoteric
May 9, 2022